<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02594033</url>
  </required_header>
  <id_info>
    <org_study_id>INS-4219</org_study_id>
    <secondary_id>U1111-1164-2873</secondary_id>
    <nct_id>NCT02594033</nct_id>
  </id_info>
  <brief_title>A Trial to Investigate Different Needle Features Assessed by Comparing Insulin Aspart Pharmacokinetic Profiles</brief_title>
  <official_title>A Single Centre, Randomised, 3-period Cross-over Trial to Investigate Different Needle Features Assessed by Comparing Insulin Aspart Pharmacokinetic Profiles</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novo Nordisk A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novo Nordisk A/S</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial is conducted in Europe. The aim of the trial is to investigate different needle
      features assessed by comparing insulin aspart Pharmacokinetics profiles (the exposure of the
      trial drug in the body)
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 27, 2015</start_date>
  <completion_date type="Actual">January 28, 2016</completion_date>
  <primary_completion_date type="Actual">January 28, 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under curve insulin aspart measured in serum</measure>
    <time_frame>During a maximum of 8 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum concentration of insulin aspart measured in serum</measure>
    <time_frame>During a maximum of 8 hours</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">46</enrollment>
  <condition>Diabetes</condition>
  <arm_group>
    <arm_group_label>3 mm needle</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>3.5 mm needle</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>4 mm needle</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>insulin aspart</intervention_name>
    <description>All subjects make three intervention visits with at least 5 days between individual intervention visits. At each intervention visit the subject receives one insulin aspart injection with only one type of needle.</description>
    <arm_group_label>3 mm needle</arm_group_label>
    <arm_group_label>3.5 mm needle</arm_group_label>
    <arm_group_label>4 mm needle</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Informed consent obtained before any trial-related activities. Trial-related
             activities are any procedures that are carried out as part of the trial, including
             activities to determine suitability for the trial

          -  Male, age at least 18 years at time of signing informed consent

          -  Considered generally healthy upon completion of medical history, physical examination,
             analysis of laboratory safety variables, vital signs and ECG (electrocardiogram), as
             judged by the investigator

          -  Body mass index (BMI) 28-39.9 kg/m^2 (overweight to obese)

          -  Caucasian

        Exclusion Criteria:

          -  Male of reproductive age who or whose partner(s) is not using adequate contraceptive
             methods (adequate contraceptive measures as required by local regulation or practice)

          -  Non-fasting blood glucose test with blood glucose values above 11.1 millimol per liter
             (mmol/L)

          -  HbA1c (Glycosylated Haemoglobin) equal to or above 6.5%

          -  Known active or in-active skin disease in the injection area or that could affect pain
             perception

          -  History of deep leg vein thrombosis or repeated episodes of deep leg vein thrombosis
             in 1st degree relatives (parents, siblings or children) as judged by the investigator

          -  Use of any prescription or non-prescription medication, including herbal products and
             nonroutine vitamins, within the last 2 weeks before screening

          -  Smoker (defined as a subject who is smoking more than 5 cigarettes or the equivalent
             per day) who is not able or willing to refrain from smoking or use of nicotine gum or
             transdermal nicotine patches during the inpatient period

          -  Known or suspected abuse of alcohol (defined as regular intake of more than 14 units
             weekly for men where 1 unit equals 300 milliliter (mL) of beer, 100 mL of wine, or 25
             mL of distilled spirits)

          -  Positive result of an alcohol breath test

          -  Known or suspected drug/chemical substance abuse within 1 year from screening
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Global Clinical Registry (GCR, 1452)</last_name>
    <role>Study Director</role>
    <affiliation>Novo Nordisk A/S</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Neuss</city>
        <zip>41460</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://novonordisk-trials.com</url>
    <description>Clinical Trials at Novo Nordisk</description>
  </link>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 30, 2015</study_first_submitted>
  <study_first_submitted_qc>October 30, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 2, 2015</study_first_posted>
  <last_update_submitted>July 31, 2017</last_update_submitted>
  <last_update_submitted_qc>July 31, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 1, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin degludec, insulin aspart drug combination</mesh_term>
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Insulin Aspart</mesh_term>
    <mesh_term>Insulin, Long-Acting</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

